TRVI insider transaction filings
Trevi Therapeutics, Inc. — 35 most recent Form 4 filings from SEC EDGAR, normalized by FilingPulse. Latest filing: 2026-06-04. Screen TRVI transaction legs live →
| Filed | Form | Insider | Reported transactions | Source |
|---|---|---|---|---|
| 2026-06-04 | 4 | Heffernan Michael Thomas — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Meeker David P — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Mathers Edward T — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | Colangelo Dominick — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-06-04 | 4 | VANLENT ANNE — Director | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Simon Farrell — Chief Commercial Officer | Grant/award (A): 160,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Galletta Christopher — See Remarks | Grant/award (A): 35,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | Cassella James V — Chief Development Officer | Grant/award (A): 215,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Grant/award (A): 85,000 (derivative) @ $0 | EDGAR |
| 2026-02-20 | 4 | GOOD JENNIFER L — President & CEO, Director | Grant/award (A): 675,000 (derivative) @ $0 | EDGAR |
| 2026-01-12 | 4 | HASTINGS DAVID C — Chief Financial Officer | Grant/award (A): 375,000 (derivative) @ $0 | EDGAR |
| 2025-12-03 | 4 | Galletta Christopher — See Remarks | Option exercise (M): 4,225 @ $0.51 · Option exercise (M): 4,225 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Heffernan Michael Thomas — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Meeker David P — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Mathers Edward T — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | Colangelo Dominick — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-13 | 4 | VANLENT ANNE — Director | Grant/award (A): 45,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Delfini Lisa — Chief Financial Officer | Grant/award (A): 72,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Simon Farrell — Chief Commercial Officer | Grant/award (A): 72,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | Galletta Christopher — See Remarks | Grant/award (A): 8,550 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Grant/award (A): 60,000 (derivative) @ $0 | EDGAR |
| 2025-06-03 | 4 | GOOD JENNIFER L — President & CEO, Director | Grant/award (A): 102,000 (derivative) @ $0 | EDGAR |
| 2025-03-26 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Option exercise (M): 2,631 @ $1.43 · Sale (S): 2,631 @ $6.60 · Option exercise (M): 2,631 (derivative) @ $0 | EDGAR |
| 2025-03-25 | 4 | GOOD JENNIFER L — President & CEO, Director | Option exercise (M): 5,263 @ $1.43 · Sale (S): 5,263 @ $6.58 · Option exercise (M): 5,263 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | Delfini Lisa — Chief Financial Officer | Grant/award (A): 38,400 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | Simon Farrell — Chief Commercial Officer | Option exercise (M): 17,500 @ $3.21 · Option exercise (M): 63,813 @ $3.91 · Option exercise (M): 31,250 @ $0.51 · Sale (S): 76,963 @ $6.73 · Sale (S): 4,350 @ $7.15 · Grant/award (A): 38,400 (derivative) @ $0 · +3 more | EDGAR |
| 2025-03-12 | 4 | Galletta Christopher — See Remarks | Grant/award (A): 4,560 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Grant/award (A): 32,000 (derivative) @ $0 | EDGAR |
| 2025-03-12 | 4 | GOOD JENNIFER L — President & CEO, Director | Grant/award (A): 54,400 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Simon Farrell — Chief Commercial Officer | Grant/award (A): 225,500 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Delfini Lisa — Chief Financial Officer | Grant/award (A): 225,500 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Galletta Christopher — See Remarks | Grant/award (A): 41,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | Cassella James V — Chief Development Officer | Grant/award (A): 257,500 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | SCIASCIA THOMAS — Chief Scientific Officer | Grant/award (A): 116,000 (derivative) @ $0 | EDGAR |
| 2025-02-20 | 4 | GOOD JENNIFER L — President & CEO, Director | Grant/award (A): 811,000 (derivative) @ $0 | EDGAR |
Recent 8-K events — Trevi Therapeutics, Inc.
| Filed | Form | Items reported | Source |
|---|---|---|---|
| 2026-08-06 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-06-04 | 8-K | 5.03 — Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year 5.07 — Submission of Matters to a Vote of Security Holders 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-05-05 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-04-17 | 8-K | 1.01 — Entry into a Material Definitive Agreement 2.02 — Results of Operations and Financial Condition 8.01 — Other Events 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-17 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2026-03-09 | 8-K | 8.01 — Other Events | EDGAR |
| 2025-12-05 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-11-13 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
| 2025-08-20 | 8-K | 5.02 — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers | EDGAR |
| 2025-08-07 | 8-K | 2.02 — Results of Operations and Financial Condition 9.01 — Financial Statements and Exhibits | EDGAR |
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?ticker=TRVI returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new ones to you in seconds. API docs →